Copyright © 2013 Jirath Wichianpitaya and Surasak Taneepanichskul. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. H. Sveindottir and T. Backstorm, “Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives,” Acta Obstetricia et Gynecologica Scandinavica, vol. 79, no. 5, pp. 405–413, 2000. View at Publisher · View at Google Scholar · View at Scopus
2. S. Taneepanichskul, “Premenstrual Symptoms Among Thai Women,” Journal of Health Research, supplement 1, p. 181, 2010.
3. N. Kurshan and C. Neill Epperson, “Oral contraceptives and mood in women with and without premenstrual dysphoria: a theoretical model,” Archives of Women's Mental Health, vol. 9, no. 1, pp. 1–14, 2006. View at Publisher · View at Google Scholar · View at Scopus
4. S. A. Winer and A. J. Rapkin, “Premenstrual disorders: prevalence, etiology and impact,” Journal of Reproductive Medicine for the Obstetrician and Gynecologist, vol. 51, no. 4, pp. 339–347, 2006. View at Scopus
5. A. M. Paoletti, S. Lello, S. Fratta et al., “Psychological effect of the oral contraceptive formulation containing 3 mg of drospirenone plus 30 μg of ethinyl estradiol,” Fertility and Sterility, vol. 81, no. 3, pp. 645–651, 2004. View at Publisher · View at Google Scholar · View at Scopus
6. American College of Obstetricians and Gynecologists, “Premenstrual syndrome,” ACOG Practice Bulletin, vol. 15, no. 9, 2000.
7. P. M. S. O'Brien, T. Backstrom, C. Brown et al., “Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus,” Archives of Women's Mental Health, vol. 14, no. 1, pp. 13–21, 2011. View at Publisher · View at Google Scholar · View at Scopus
8. P. J. Sulak, R. D. Scow, C. Preece, M. W. Riggs, and T. J. Kuehl, “Hormone withdrawal symptoms in oral contraceptive users,” Obstetrics and Gynecology, vol. 95, no. 2, pp. 261–266, 2000. View at Publisher · View at Google Scholar · View at Scopus
9. P. J. Sulak, J. Carl, I. Gopalakrishnan, A. Coffee, and T. J. Kuehl, “Outcomes of extended oral contraceptive regimens with a shortened hormone-free interval to manage breakthrough bleeding,” Contraception, vol. 70, no. 4, pp. 281–287, 2004. View at Publisher · View at Google Scholar · View at Scopus
10. J. Spona, M. Elstein, W. Feichtinger et al., “Shorter pill-free interval in combined oral contraceptives decreases follicular development,” Contraception, vol. 54, no. 2, pp. 71–77, 1996. View at Publisher · View at Google Scholar · View at Scopus
11. H. Sullivan, H. Furniss, J. Spona, and M. Elstein, “Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 μg) and ethinyl estradiol (15 μg) on ovarian activity,” Fertility and Sterility, vol. 72, no. 1, pp. 115–120, 1999. View at Publisher · View at Google Scholar · View at Scopus
12. T. B. Pearlstein, G. A. Bachmann, H. A. Zacur, and K. A. Yonkers, “Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation,” Contraception, vol. 72, no. 6, pp. 414–421, 2005. View at Publisher · View at Google Scholar · View at Scopus
13. U. H. Winkler, H. Ferguson, and J. A. P. A. Mulders, “Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 μg ethinylestradiol,” Contraception, vol. 69, no. 6, pp. 469–476, 2004. View at Publisher · View at Google Scholar · View at Scopus
14. L. M. Lopez, A. Kaptein, and F. M. Helmerhorst, “Oral contraceptives containing drospirenone for premenstrual syndrome,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD006586, 2009. View at Publisher · View at Google Scholar · View at Scopus
15. R. H. Moos, “Typology of menstrual cycle symptoms,” American Journal of Obstetrics and Gynecology, vol. 103, no. 3, pp. 390–402, 1969. View at Scopus
16. M. Sangthawan and S. Taneepanichskul, “A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 μg on premenstrual symptoms,” Contraception, vol. 71, no. 1, pp. 1–7, 2005. View at Publisher · View at Google Scholar · View at Scopus
17. S. Taneepanichskul, U. Jaisamrarn, and V. Phupong, “Efficacy of Yasmin in premenstrual symptoms,” Archives of Gynecology and Obstetrics, vol. 275, no. 6, pp. 433–438, 2007. View at Publisher · View at Google Scholar · View at Scopus
18. R. Kroll and A. J. Rapkin, “Treatment of premenstrual disorders,” Journal of Reproductive Medicine for the Obstetrician and Gynecologist, vol. 51, no. 4, pp. 359–370, 2006. View at Scopus
19. S. A. Willis, T. J. Kuehl, A. M. Spiekerman, and P. J. Sulak, “Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval,” Contraception, vol. 74, no. 2, pp. 100–103, 2006. View at Publisher · View at Google Scholar · View at Scopus
20. J. Borenstein, H. T. Yu, S. Wade, C. F. Chiou, and A. Rapkin, “Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life,” Journal of Reproductive Medicine for the Obstetrician and Gynecologist, vol. 48, no. 2, pp. 79–85, 2003. View at Scopus
21. G. Bachmann, P. J. Sulak, C. Sampson-Landers, N. Benda, and J. Marr, “Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 μg ethinylestradiol and 3 mg drospirenone,” Contraception, vol. 70, no. 3, pp. 191–198, 2004. View at Publisher · View at Google Scholar · View at Scopus
22. K. A. Yonkers, C. Brown, T. B. Pearlstein, M. Foegh, C. Sampson-Landers, and A. Rapkin, “Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder,” Obstetrics and Gynecology, vol. 106, no. 3, pp. 492–501, 2005. View at Scopus
23. P. M. S. O’Brien, “The premenstrual syndrome, a review,” The Journal of Reproductive Medicine, vol. 30, pp. 113–126, 1985.
24. A. Rubig, “Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties,” Climacteric, vol. 6, no. 3, pp. 49–54, 2003. View at Scopus
25. D. M. Dougherty, J. M. Bjork, F. G. Moeller, and A. C. Swann, “The influence of menstrual-cycle phase on the relationship between testosterone and aggression,” Physiology and Behavior, vol. 62, no. 2, pp. 431–435, 1997. View at Publisher · View at Google Scholar · View at Scopus
26. A. J. Rapkin and S. A. Winer, “Drospirenone: a novel progestin,” Expert Opinion on Pharmacotherapy, vol. 8, no. 7, pp. 989–999, 2007. View at Publisher · View at Google Scholar · View at Scopus
27. R. Krattenmacher, “Drospirenone: pharmacology and pharmacokinetics of a unique progestogen,” Contraception, vol. 62, no. 1, pp. 29–38, 2000. View at Publisher · View at Google Scholar · View at Scopus
28. S. A. Winer and A. J. Rapkin, “Premenstrual disorders: prevalence, etiology and impact,” Journal of Reproductive Medicine for the Obstetrician and Gynecologist, vol. 51, no. 4, pp. 339–347, 2006. View at Scopus